Physician profile
Arthur Friedman
NPI 1194710301
$622.10
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.38 | 2019 | |
| Pfizer INC. | $80.39 | 2019-2020 | |
| Amarin Pharma, INC. | $55.54 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $48.25 | 2019-2020 | |
| Amgen INC. | $47.78 | 2019-2020 | |
| Allergan, INC. | $41.05 | 2019-2020 | |
| Horizon Therapeutics Plc | $37.82 | 2019-2020 | |
| Novo Nordisk INC | $36.49 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.74 | 2019 | |
| Glaxosmithkline, LLC. | $18.74 | 2019 | |
| Daiichi Sankyo INC. | $18.49 | 2019 | |
| Merck Sharp & Dohme LLC | $16.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.